Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - SCYNEXIS INC | exhibit311.htm |
| EX-32.1 - EXHIBIT 32.1 - SCYNEXIS INC | exhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 - SCYNEXIS INC | exhibit312.htm |
| EX-23.1 - EXHIBIT 23.1 - SCYNEXIS INC | exhibit231.htm |
| EX-12.1 - EXHIBIT 12.1 - SCYNEXIS INC | exhibit121.htm |
| EX-10.35 - EXHIBIT 10.35 - SCYNEXIS INC | exhibit1035.htm |
| EX-10.30 - EXHIBIT 10.30 - SCYNEXIS INC | exhibit1030.htm |
| 10-K - 10-K - SCYNEXIS INC | form10-k.htm |
Exhibit 10.34
On January 31, 2017, the Board of Directors of SCYNEXIS, Inc. took the following compensation actions with respect to SCYNEXIS’s following executive officers (collectively, the “Officers”):
2016 Officer Bonuses
Approved cash bonuses for the Officers based on SCYNEXIS’s performance for the calendar year 2016:
Executive Officer | Title | Bonus | ||
Marco Taglietti, M.D. | Chief Executive Officer | $210,100 | ||
David Angulo, M.D. | Chief Medical Officer | $136,600 | ||
Eric Francois | Chief Financial Officer | $113,000 | ||
2017 Salaries
Approved the 2017 salaries for the Officers, to be effective March 1, 2017, as follows:
Executive Officer | Title | 2017 Salary | ||
Marco Taglietti, M.D. | Chief Executive Officer | $510,000 | ||
David Angulo, M.D. | Chief Medical Officer | $413,800 | ||
Eric Francois | Chief Financial Officer | $360,500 | ||
Option Grants
Approved stock option grants under SCYNEXIS 's 2014 Equity Incentive Plan to the following Officers:
Executive Officer | Title | Shares subject to Option | ||
Marco Taglietti, M.D. | Chief Executive Officer | 360,000 | ||
David Angulo, M.D. | Chief Medical Officer | 140,000 | ||
Eric Francois | Chief Financial Officer | 100,000 | ||
The options have an exercise price of $3.02 per share and vest on a monthly basis over a four-year period, provided such officer is continuing to provide services to SCYNEXIS on such vesting date.